Back to Search Start Over

Low level of tumor necrosis factor α in tumor microenvironment maintains self-renewal of glioma stem cells by Vasorin-mediated glycolysis.

Authors :
Zhang Y
Kang T
Wang Y
Song C
Li H
Mi H
Li Y
Dong M
Ma X
Zhu H
Cheng L
Zhang P
Chen Z
Zhou L
Wu Q
Mao F
Wang B
Zhang S
Shu K
Wan F
Zhou W
Rich JN
Shen J
Xiao Q
Yu X
Source :
Neuro-oncology [Neuro Oncol] 2024 Aug 02. Date of Electronic Publication: 2024 Aug 02.
Publication Year :
2024
Publisher :
Ahead of Print

Abstract

Background: Self-renewal of glioma stem cells (GSCs) is responsible for glioblastoma (GBM) therapy-resistant and recurrence. Tumor necrosis factor α (TNFα) and TNF signaling pathway display an antitumor activity in preclinical models and in tumor patients. However, TNFα exhibits no significance for glioma clinical prognosis based on Glioma Genome Atlas database. This study aimed to explore whether TNFα of tumor microenvironment maintains self-renewal of GSCs and promotes worse prognosis in glioma patient.<br />Methods: Spatial transcriptomics, immunoblotting, sphere formation assay, extreme limiting dilution, and gene expression analysis were used to determine the role of TNFα on GSC's self-renewal. Mass spectrometry, RNA-sequencing detection, bioinformatic analyses, qRT-RNA, immunofluorescence, immunohistochemistry, single cell RNA sequencing, in vitro and in vivo models were used to uncover the mechanism of TNFα-induced GSC self-renewal.<br />Results: Low level of TNFα displays a promoting effect on GSC self-renewal and worse glioma prognosis. Mechanistically, Vasorin (VASN) mediated TNFα-induced self-renewal by potentiating glycolysis. Lactate produced by glycolysis inhibits the TNFα secretion of tumor-associated macrophages (TAMs) and maintains TNFα in a low level.<br />Conclusions: TNFα-induced GSC self-renewal mediated by VASN provides a possible explanation for the failures of endogenous TNFα effect on GBM. Combination of targeting VASN and TNFα anti-tumor effect may be an effective approach for treating GBM.<br /> (© The Author(s) 2024. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.)

Details

Language :
English
ISSN :
1523-5866
Database :
MEDLINE
Journal :
Neuro-oncology
Publication Type :
Academic Journal
Accession number :
39093693
Full Text :
https://doi.org/10.1093/neuonc/noae147